{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:34:07Z","timestamp":1772253247673,"version":"3.50.1"},"reference-count":37,"publisher":"Baishideng Publishing Group Inc.","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2015]]},"DOI":"10.3748\/wjg.v21.i29.8935","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T02:23:18Z","timestamp":1438827798000},"page":"8935","source":"Crossref","is-referenced-by-count":22,"title":["Interferon-\u03bb polymorphisms and response to pegylated interferon in Iranian hepatitis C patients"],"prefix":"10.3748","volume":"21","author":[{"given":"Arghavan","family":"Haj-sheykholeslami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"World Health Organization Hepatitis C: World Health Organization; 2015;."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2009.11.032"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu012"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.6151"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02296.x"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045698"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.22649"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23850"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05197.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-6"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.","DOI":"10.1016\/0168-8278(95)80226-6"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997;35:201-207.","DOI":"10.1128\/JCM.35.1.201-207.1997"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.849"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Sharieff KA, Duncan D, Younossi Z. Advances in treatment of chronic hepatitis C: ‘pegylated’ interferons. Cleve Clin J Med 2002;69:155-159.","DOI":"10.3949\/ccjm.69.2.155"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:iii-iv, 1-125.","DOI":"10.3310\/hta8390"},{"key":"ref19","unstructured":"Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, Zamini H, Shahzamani K, Merat S, Nassiri-Toosi M. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med 2010;13:306-312."},{"key":"ref20","unstructured":"Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, Zamini H, Merat S, Malekzadeh R, Sharfi AH. Pegaferon in hepatitis C: Results of a Multicenter Study. Middle East J Dig Dis 2011;3:110-114."},{"key":"ref21","unstructured":"Alavi Moghaddam M, Zali MR, Aalaei Andabili SH, Derakhshan F, Miri SM, Alavian SM. High Rate of Virological Response to Peginterferon α-2a-Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C. Iran Red Crescent Med J 2012;14:466-469."},{"key":"ref22","unstructured":"Yenice N, Mehtap O, Gümrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006;17:94-98."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01402.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Yan KK, Guirgis M, Dinh T, George J, Dev A, Lee A, Zekry A. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008;14:3416-3420.","DOI":"10.3748\/wjg.14.3416"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Lin CY, Sheen IS, Jeng WJ, Huang CW, Huang CH, Chen JY. Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism. Ann Hepatol 2013;12:62-69.","DOI":"10.1016\/S1665-2681(19)31386-9"},{"key":"ref26","unstructured":"Gheorghe L, Iacob S, Grigorescu M, Sporea I, Sirli R, Damian D, Gheorghe C, Iacob R. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C. J Gastrointestin Liver Dis 2009;18:51-56."},{"key":"ref27","unstructured":"Rashidi RNTM, Shah Siya R, Forutan H, Merat SH, Ebrahimi Daryani N. The Effect of Interleukin 28 B Polymorphism on Sustained Virology Response (SVR) in Patients with Chronic Hepatitis C. Govaresh 2010;15."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12589"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.8387"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.08.027"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12384"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.13678"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080172"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.051052-0"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.022"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i35.4892"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06834.x"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i29\/8935.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T18:44:37Z","timestamp":1599417877000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v21\/i29\/8935.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":37,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v21.i29.8935","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725718665.793509043","asserted-by":"object"}]},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}